Steba Biotech Ltd.

ImPact Biotech is a clinical-stage biotechnology company focused on developing and commercializing Padeliporfin Vascular Targeted Photodynamic (VTP) therapy, a minimally invasive treatment for solid tumors. This novel technology platform uses a photosensitive drug, Padeliporfin, activated by non-thermal laser light to selectively target and ablate tumors. ImPact's primary focus is on treating a range of solid tumors, including upper tract urothelial carcinoma (UTUC), lung cancer, esophageal cancer, and pancreatic cancer.

The company is headquartered in Israel with divisions in the USA and France. They have their own GMP-certified facility and research center in Israel, and collaborate with the Weizmann Institute of Science and Memorial Sloan Kettering Cancer Center to advance their research and clinical development programs. ImPact is committed to delivering precise, safe, and effective therapeutic solutions for patients with cancer, offering a potential alternative to surgery where it is not possible or desirable.

ImPact Biotech is a clinical-stage oncology company focused on developing and commercializing Padeliporfin Vascular Targeted Photodynamic (VTP) therapy, a minimally invasive drug-device combination designed for selective ablation of unresectable solid tumors. Their mission is to deliver precise, safe, and effective therapeutic solutions for cancer patients, offering surgery-like efficacy in cases where traditional surgery is either debilitating or not practical. ImPact Biotech believes their technology has the potential to significantly impact the lives of patients facing challenging cancers, allowing them to confidently face the challenges of their disease while maintaining their quality of life.

ImPact Biotech fosters a culture of innovation and collaboration, driven by a shared passion for developing groundbreaking therapies that improve patient lives. They prioritize a fast-paced, results-oriented environment, valuing scientific expertise, teamwork, and a commitment to excellence. The company's dedication to scientific advancement is evident in its partnerships with leading institutions like the Weizmann Institute of Science and Memorial Sloan Kettering Cancer Center, creating a dynamic and intellectually stimulating atmosphere.